Efficacy of oral colon-specific delivery capsule of low-molecular-weight heparin on ulcerative colitis

Biomedicine and Pharmacotherapy

Volumn 65, Issue 2, 2011, Pages 111-117

  Luo, Jun Yong ^a   Zhong, Yan ^a   Cao, Ji Chao ^a   Cui, Hui Fei ^a  

^a SHANDONG UNIVERSITY   (China)

Author keywords

Colon specific delivery capsule; Inflammatory bowel disease; Low molecular weight heparin; Ulcerative colitis; Unfractioned heparin

Indexed keywords

BLOOD CLOTTING FACTOR 10A; INTERLEUKIN 6; LOW MOLECULAR WEIGHT HEPARIN; MYELOPEROXIDASE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; ENZYME ACTIVITY; FEMALE; HISTOPATHOLOGY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ULCERATIVE COLITIS;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; COLITIS, ULCERATIVE; COLON; DALTEPARIN; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR XA; FEMALE; INTERLEUKIN-6; MALE; MICE; NERVE TISSUE PROTEINS; RNA-BINDING PROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954612101     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopha.2010.12.013     Document Type: Article

References (39)

1. Xia B., Han H., Zhang K.J., et al. Effects of low molecular weight heparin on platelet surface P-selectin expression and serum interleukin-8 production in rats with trinitrobenzene sulphonic acid-induced colitis. World J Gastroenterol 2004, 10:729-732.
2. Wan M.X., Liu Q., Wang Y., Thorlacius H. Protective effect of low molecular weight heparin on experimental colitis: role of neutrophil recruitment and TNF-α production. Inflamm Res 2002, 51:182-187.
3. Celasco G, Moro L., Bozzella R., et al. Efficacy of intracolonic administration of low-molecular-weight heparin CB-01-05, compared to other low-molecular-weight heparins and unfractionated heparin, in experimentally induced colitis in rat. Dig Dis Sci 2008, 53:3170-3175.
4. Cahalon L., Lider O., Schor H., et al. Heparin disaccharides inhibit tumor necrosis factor-a production by macrophages and arrest immune inflammation in rodents. Int Immunol 1997, 9:1517-1522.
5. Torkvist L., Thorlacius H., Sjoqvist U., et al. Low molecular weight heparin as adjuvant therapy inactive ulcerative colitis. Aliment Pharmacol Ther 1999, 13:1323-1328.
6. Folwaczny C., Wiebecke B., Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999, 94:1551-1555.
7. Evans R.C., Wong V.S., Morris A.I., et al. Treatment of corticosteroid-resistant ulcerative colitis with heparin - a report of 16 cases. Aliment Pharmacol Ther 1997, 11:1037-1040.
8. Ang Y.S., Mahmud N., White B., et al. Randomized comparison of unfractionated heparin with corticosteroids in severe active inflammatory bowel disease. Aliment Pharmacol Ther 2000, 14:1015-1022.
9. Dotan I., Hallak A., Arber N., et al. Low dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 2001, 46:2239-2244.
10. Dhaneshwar S.S., Chail M., Patil M., et al. Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats. Eur J Med Chem 2009, 44:131-142.
11. Bott C., Rudolph M.W., Schneider A.R.J., et al. In vivo evaluation of a novel pH- and time-based multiunit colonic drug delivery system. Aliment Pharmacol Ther 2004, 20:347-353.
12. Yang L., Chu J.S., Fix J.A. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 2002, 235:1-15.
13. Tuleu C., Basit A.W., Waddington W.A., et al. Colonic delivery of 4-aminosalicylic acid using amylose-ethylcellulose-coated hydroxypropyl-methylcellulose capsules. Aliment Pharmacol Ther 2002, 16:1771-1779.
14. Cui H.F., Jiang X.L. Treatment of corticosteroid-resistant ulcerative colitis with oral low molecular weight heparin. World J Gastroenterol 1999, 5:448-450.
15. Pellequer Y., Meissner Y., Ubrich N., et al. Epithelial heparin delivery via microspheres mitigates experimental colitis in mice. J Pharmacol Exp Ther 2007, 321:726-733.
16. Pastorelli L., Saibeni S., Spina L., et al. Oral, colonic release low molecular weight heparin: an initial open study of parnaparin-MMX for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2008, 28:581-588.
17. Maines L.W., Fitzpatrick L.R., French K.J., et al. Suppression of ulcerative colitis in mice by orally-available inhibitors of sphingosine kinase. Dig Dis Sci 2008, 53:997-1012.
18. Fitzpatrick L.R., Wang J., Le M. In vitro and in vivo effects of gliotoxin, a fungal metabolite: efficacy against dextran sodium sulfate-induced colitis in rats. Dig Dis Sci 2000, 45:2327-2336.
19. Basit A.W. Advances in colonic drug delivery. Drugs 2005, 65:1991-2007.
20. Chourasia M.K., Jain S.K. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharm Sci 2003, 6:33-66.
21. Rubinstein A. Approaches and opportunities in colon-specific drug delivery. Crit Rev Ther Drug Carrier Syst 1995, 12:101-149.
22. Friend D.R. New oral delivery systems for treatment of inflammatory bowel disease. Adv Drug Deliv Rev 2005, 57:247-265.
23. Sinha V.R., Kumria R. Microbially triggered drug delivery to the colon. Eur J Pharm Sci 2003, 18:3-18.
24. Vandamme T.F., Lenourry A., Charrueau C., et al. The use of polysaccharides to target drugs to colon. Carbohydr Polym 2002, 48:219-231.
25. Krawisz J.E., Sharon P., Stenson W.F. Quantitative assay for acute intestinal inflammation based on myeloperoxidase. Gastroenterology 1984, 87:1344-1350.
26. Deventer S.J.H. Tumor necrosis factor and Crohn's disease. Gut 1997, 40:443-448.
27. Gonzalez-Lama Y., Fernandez-Blanco I., Lopez-SanRoman A., et al. Open-label infliximab therapy in ulcerative colitis: a multicenter survey of results and predictors of response. Hepatogastroenterology 2008, 5:1609-1614.
28. Hyams J.S., Lerer T., Griffiths A., et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009, 15:816-822.
29. Polgar A., Brozik M., Toth S., et al. Soluble interleukin-6 receptor in plasma and in lymphocyte culture supernatants of healthy individuals and patients with systemic lupus erythematosus and rheumatoid arthritis. Med Sci Monit 2000, 6:13-18.
30. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
31. Herbert J.M., Bono F., Herault J.P., et al. Effector protease receptor 1 mediates the mitogenic activity of factor Xa for vascular smooth muscle cells in vitro and in vivo. Clin Invest 1998, 101:993-1000.
32. Papapetropoulos A., Piccardi P., Cirino G., et al. Hypotension and inflammatory cytokine gene expression triggered by factor Xa-nitric oxide signaling. Proc Natl Acad Sci U S A 1998, 95:4738-4742.
33. Joo S.S., Won T.J., Kim J.S., et al. Inhibition of coagulation activation and inflammation by a novel factor Xa inhibitor synthesized from the earthworm Eisenia andrei. Biol Pharm Bull 2009, 32:253-258.
34. Saifeddine M., Al-Ani B., Cheng C.H., et al. Rat proteinase activated receptor-2 (PAR-2): cDNA sequence and activity of receptor-derived peptides in gastric and vascular tissue. Br J Pharmacol 1996, 118:521-530.
35. Okano H., Kawahara H., Toriya M., et al. Function of RNA-binding protein Musashi-1 in stem cells. Exp Cell Res 2005, 306:349-356.
36. Potten C.S., Booth C., Tudmor G.L., et al. Identification of a putative intestinal stem cell and early lineage marker; Musashi-1. Differentiation 2003, 71:28-41.
37. Kayahara T., Sawada M., Takaishi S., et al. Chiba T candidate markers for stem and early progenitor cells, Musashi-1 and Hes1, are expressed in crypt base columnar cells of mouse small intestine. FEBS Lett 2003, 535:131-135.
38. Sakatani T., Kaneda A., Iacobuzio-Donahue C.A., et al. Loss of imprinting of Igf2 alter intestinal maturation and tumorigenesis in mice. Science 2005, 307:1976-1978.
39. Murata H., Tsuji S., Tsujii M., et al. Helicobacter pylori infection induces candidate stem cell marker Musashi-1 in the human gastric epithelium. Dig Dis Sci 2008, 53:363-369.